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Stromal cell-derived factor-1alpha (SDF-1α) has pleiotropic eﬀects on hematopoietic progenitor cells (HPCs). We have monitored
podia formation, migration, proliferation, and cell-cell adhesion of human HPC under the inﬂuence of SDF-1α, a peptide agonist
of CXCR4 (CTCE-0214), a peptide antagonist (CTCE-9908), and a nonpeptide antagonist (AMD3100). Whereas SDF-1α induced
m i g r a t i o no fC D 3 4 + cells in a dose-dependent manner, CTCE-0214, CTCE-9908, and AMD3100 did not induce chemotaxis in
this concentration range albeit the peptides CTCE-0214 and CTCE-9908 increased podia formation. Cell-cell adhesion of HPC
to human mesenchymal stromal cells was impaired by the addition of SDF-1α, CTCE-0214, and AMD3100. Proliferation was not
aﬀected by SDF-1α or its analogs. Surface antigen detection of CXCR4 was reduced upon treatment with SDF-1α or AMD3100
and it was enhanced by CTCE-9908. Despite the fact that all these molecules target the same CXCR4 receptor, CXCR4 agonists
and antagonists have selective eﬀects on diﬀerent functions of the natural molecule.
Copyright © 2007 Anne Faber et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Stromal cell-derived factor-1 (SDF-1 or CXCL12) is a mul-
tifunctional cytokine that is constitutively expressed and se-
creted by several tissues, including endothelium and stromal
cells [1, 2]. It has a single open reading frame of 282 nu-
cleotides encoding a polypeptide of 93 amino acids. SDF-
1 arises in two forms, SDF-1α (amino acids 24–88) and
SDF-1β (amino acids 24–93), by diﬀerential splicing [3–5].
SDF-1α is so far the only proven chemoattractant for prim-
itive hematopoietic progenitor cells (HPC) [6–8]. Accord-
ingly, SDF-1α is considered as one of the key regulators for
hematopoietic progenitor cell traﬃcking between the pe-
ripheral circulation and bone marrow [54]. Our group and
others have demonstrated that SDF-1α induces polarization
and podia formation of HPC and leukemic cells [9, 10], two
properties that represent prerequisites for directed locomo-
tion. SDF-1α alone showed a moderate eﬀect on cell pro-
liferation in CD34+ cells [11], and its eﬀect on survival or
apoptosis of HPC has remained controversial [12–15]. Fur-
thermore the SDF-1α/CXCR4 axis plays a crucial role in reg-
ulation of homing and adhesion to the supportive cellular
microenvironment in the stem cell niche [16].
The receptor for SDF-1α has been identiﬁed as the 7-
t r a n s m e m b r a n er e c e p t o rC X C R 4w h i c hi sa l s oac o r e c e p -
tor for the HIV type 1 virus [17, 18]. SDF-1α/CXCR4 in-
teraction was reported to play an important role during
embryonic development, especially in hematopoiesis, vascu-
lar development, and cardiogenesis. CXCR4 expression on
bone marrow endothelial cells is important for internaliza-
tion of circulating SDF-1α, resulting in its translocation into
the bone marrow [2]. CXCR4 is also expressed on primi-
tive CD34+ HPC [11]. Signal transduction pathways initi-
ated by the binding of SDF-1α to CXCR4 are not fully un-
derstood. Mechanisms involved in CXCR4 signaling include
Gi-protein-mediated activation of PI3K and the phospholi-
pase C cascade [6, 19, 20].
The function of SDF-1α can be mimicked by small pep-
tide agonists [21]. Such molecules have several advantages
over the natural one such as the ease of manufacturing and2 Journal of Biomedicine and Biotechnology
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Figure 1: SDF-1α/CXCR4 axis and interaction with small
molecules. The chemokine stromal cell-derived factor-1 alpha
(SDF-1αorCXCL12)issecretedbystromalcellswithvariouseﬀects
on hematopoietic progenitor cells (HPCs). It binds to the CXCR4
receptor and this interaction can be inﬂuenced by the peptide ago-
nist CTCE-0214 as well as by the peptide antagonists CTCE-9908 or
the nonpeptide antagonist AMD3100.
that they can be more resistant to serum modiﬁcation and
inactivation [22]. CTCE-0214, for example, is an analog
in which the C-terminal of SDF-1α is connected to the
N-terminal region by a short bifunctional linker. A recent
publication suggested that CTCE-0214 might improve ex
vivo expansion and engraftment of HPC in a mouse model
[23]. CTCE-0214 has also been reported to increase circu-
lating HPC concentrations when administered to a murine
model, indicating that this SDF-1α peptide agonist could
be used for mobilization [24]. CTCE-9908 is another small
peptide analog that comprises a dimerized sequence of
the disordered N-terminal region of SDF-1α and was de-
signed to block the CXCR4 receptor. Furthermore, nonpep-
tide compounds have been used to interfere with the SDF-
1α/CXCR4 axis. AMD3100, for example, is a bicyclam in
which the two cyclam rings are tethered by an aromatic
bridge. It was ﬁrst designed as an inhibitor of virus repli-
cation of HIV-1 and HIV-2 [25]. However, AMD3100 has
been shown to be a very potent and selective inhibitor
of CXCR4 and both experimental and clinical data sug-
gest that AMD3100 might mobilize a more primitive and
hence multipotent HPC population than G-CSF [26, 27].
The diﬀerent peptide and nonpeptide analogs might have a
more selective eﬀect with respect to the diﬀerent functions
of the native molecule SDF-1α (Figure 1). Here, we have
compared eﬀects of SDF-1α, CTCE-0214, CTCE-9908, and
AMD3100 on polarization, migration, adhesion, prolifera-
tion, and CXCR4 receptor internalization in human CD34+
cells.
2. METHODS
2.1. Isolationofhematopoieticprogenitorcells
HPCs were collected from fresh umbilical cord blood after
informed consent using guidelines approved by the Ethic
Committee on the Use of Human Subjects at the University
of Heidelberg. Mononuclear cells (MNCs) were isolated af-
ter density gradient centrifugation on Ficoll-hypaque tech-
nique (Biochrom KG, Berlin, Germany). CD34+ cells were
enriched by labeling with a monoclonal anti-CD34 anti-
body conjugated with magnetic MICROBEADS in an Au-
toMACS system (Miltenyi Biotec, Bergisch-Gladbach, Ger-
many). Further puriﬁcation was achieved using the auto-
matic cell depositing unit on an FACS-Vantage-SE ﬂow cy-
tometry sorting system after additional staining with anti-
CD34-phycoerythrin (PE) (Becton Dickinson (BD), San
Jose, Calif, USA). Staining with propidium iodide (PI) was
performed prior to sorting to allow exclusion of nonviable
cells.
2.2. CXCR4agonistsandantagonists
The following analogs of SDF-1α were used: SDF-1α (Sigma-
Aldrich, St. Louis, Mo, USA); CTCE-0214, peptide ago-
nist of CXCR4 (amino acid sequence: KPVSLSYRAPFRFF-
Linker-LKWIQEYLEKALN) [23, 24]; CTCE-9908, peptide
antagonist of CXCR4 (amino acid sequence: KGVSLSYR-
X-RYSLSVGK; both compounds were kindly donated by
Chemokine Therapeutics Corporation, Vancouver, Canada);
and AMD3100, nonpeptide antagonist of CXCR4 (courtesy
of AnorMED, Langley, Canada).
2.3. Invitrotwo-chambermigrationassay
Chemotaxis was assessed by a transwell-migration assay.
Iscove’s Modiﬁed Dulbecco’s medium (IMDM; Cambrex,
Walkersville, Md, USA) with 20% FCS and diﬀerent con-
centrations of CXCR4 agonists or antagonists as mentioned
above were added to the lower chamber of a Falcon Tran-
swell (3μm pore size, Becton Dickinson). Equal cell num-
bers were seeded in the upper chamber in medium without
CXCR4 agonists or antagonists. After 2 hours, the transwells
were removed and cells that had migrated through the mi-
cropores into the lower chamber were counted in a counting
chamber. As the cell numbers of available CD34+ cells var-
ied between experiments, the fold-increase of migrating cells
was calculated relative to the corresponding control without
cytokines.
2.4. Cellmorphologyanalysisbymicroscopy
CD34+ cells were seeded in IMDM medium with 20% FCS
with SDF-1α, CXCR4 agonists or antagonists for 4 hours.
Cell morphology was assessed with an Olympus IX70 ﬂu-
orescence microscope (Olympus Optical, Hamburg, Ger-
many). Phase contrast pictures were taken from at least 3 re-
gions in each well in each of ﬁve independent experiments.Anne Faber et al. 3
The ratio of round cells compared to polarized cells with a
prominent uropod was determined.
2.5. CelldivisionanalysisuponCFSEstaining
CD34+ cells were labeled with carboxyﬂuorescein diacetate
N-succinimidyl ester (CFSE; Sigma-Aldrich, Steinheim, Ger-
many) to monitor cell division. In brief, cells were washed
in PBS with 0.1% FCS and then stained with CFSE at
a ﬁnal concentration of 0.3μMf o r1 0m i n u t e sa t3 7 ◦C.
Staining reaction was stopped with ice cold RPMI with
20% FCS for 5 minutes with three subsequent washes.
The labelled cells were cultured for 7 days in RPMI-1640
medium with 20% FCS with CXCR4 agonists or antag-
onists (500ng/mL) as mentioned above. Alternatively, the
cells were cultured for 5 days in Myelocult (Stem Cell Tech-
nology, Vancouver, Canada) supplemented with a cytokine
cocktail (2.5U/mL erythropoietin, 10ng/mL interleukin-3,
500U/mL interleukin-6, 10ng/mL granulocyte-macrophage
colony-stimulating factor, 2.5ng/mL basic ﬁbroblast growth
factor, 10ng/mL insulin-like growth factor-1, 50ng/mL stem
cell factor, and 2.5ng/mL ﬁbroblast growth factor-beta) as
described previously [28, 29] .C e l l sw e r et h e na n a l y z e db y
ﬂow cytometry according to their CFSE staining. Dead cells
were discriminated as PI positive. The number of cell divi-
sionscouldbeestimatedbytheperiodicaldilutionofresidual
C F S Ed y et od a u g h t e rc e l l s .
2.6. Adhesionassay
Adhesive cell-cell interaction was analyzed on a feeder layer
of human mesenchymal stromal cells (MSCs) from hu-
man bone marrow (BM), which were isolated in the cul-
ture medium described by Reyes et al. [30]a n dW a g n e r
et al. [31, 32]. Negative control adhesion was analyzed on
glass surface upon coating for 15 minutes with 10ng/mL ﬁ-
bronectin (Sigma-Aldrich) or 2.5g/dL bovine serum albu-
min (BSA; PAA, C¨ olbe, Germany). The percentage of adher-
ent cells was quantiﬁed with our novel adhesion assay [33].
In brief, adhesive press-to-seal silicone isolators with eight
wells, 9mm diameter, 1.0mm deep (Invitrogen, Karlsruhe,
Germany) were ﬁxed on glass slides. Feeder layer cells were
seeded in these wells in a density of about 105 cells/cm2 and
were grown for 24–72 hours at 37◦C and 5% CO2 until they
formed a conﬂuent cell layer. All adhesion experiments were
performed in IMDM supplemented with 20% FCS, Peni-
cillin 1000U/mL, and Streptomycin 100U/mL. HPCs were
stained with the ﬂuorescent membrane dye PKH26 (Sigma-
Aldrich) before use [34–37]. About 10 000 HPC were seeded
per well and were allowed to settle for 15 minutes. A cover
slide was sealed airtight on the silicone spacer and cells were
allowed to adhere for additional 45 minutes. HPCs were then
analyzed on the feeder layer cells with an Olympus IX70
ﬂuorescence microscope (Olympus Optical, Hamburg, Ger-
many) using a dual-band ﬂuorescence ﬁlter set FITC/Cy3
(AHFAnalysetechnik,T¨ ubingen,Germany).Themicroscope
was equipped with an incubation box to keep a constant
temperature of 37◦C and 5% CO2. The experimental setting
was then inverted 180◦. Adherent cells remained attached to
feeder layer cells, whereas nonadherent cells dropped down
and could be observed on the focus level of the cover slide.
Fluorescent images were always taken from the same region
before the inversion (all cells on the feeder layer = ALL)a s
well as after the inversion in the focus level of feeder layer
cells(adherentcells =ADH),andonthelowerglassslidelevel
(nonadherent cells = NON-ADH). Cells were counted in 3–
6d i ﬀerent regions in each well. Three independent experi-
ments were performed in duplicate with each of the SDF-1α
analogs, and a control without these compounds was always
analyzed in parallel. Percentage of adherent cells was always
calculated by two methods: (1) ADH/ALL;( 2 )ADH/(ADH
+ NON-ADH), and these results were always consistent.
2.7. FlowcytometricanalysisofCXCR4
Auto-MACS enriched CD34+ cells or BM-MSC were in-
cubated with SDF-1α analogs (500ng/mL) for 30 minutes
at 37◦C. Cells were then either washed twice with ice-cold
PBS before antibody staining or the antibodies were incu-
bated together with the SDF-1α analogs. Cells were stained
with anti-CXCR4-phycoerythrin (PE; clone 12G5) and anti-
CD34-allophycocyanin (APC) (both BD Biosciences) for ad-
ditional 30 minutes at 4◦C, washed in PBS 4◦C, and imme-
diately analyzed by ﬂow cytometry to determine surface ex-
pression of CXCR4.
2.8. Statistics
All results are expressed as mean ± standard deviation. To
estimate the probability of diﬀerences, we have adopted the
paired Student t test. Probability value of P<. 05 denoted
statistical signiﬁcance.
3. RESULTS
3.1. Effectsonmigration
Chemotaxis of CD34+ cells towards a gradient of SDF-1α
and CXCR4 agonists or antagonists was assessed in a tran-
swell migration assay. The number of migratory cells in-
creased continuously with the SDF-1α concentration of up
to 500ng/mL SDF-1α [9]. In contrast, neither the agonist
CTCE-0214 nor the antagonists CTCE-9908 or AMD3100
induced any signiﬁcant migration under these conditions
(Figure 2(a)). However, a further increase in the concentra-
tion of CTCE-0214 (100μg/mL) resulted in a moderate in-
crease in migration of CD34+ cells.
3.2. Effectsonpodiaformation
Polarization and podia formation are prerequisites for di-
rected locomotion of HPC. We have analyzed the podia for-
mation of CD34+ cells upon 4-hour treatment with SDF-
1α, CXCR4 agonists or CXCR4 antagonists. Consistent with
our previous report 15% (±2%) of the cells demonstrated
an elongated morphology with a prominent uropod in the4 Journal of Biomedicine and Biotechnology
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Figure 2: Eﬀects on cell migration and podia formation.The eﬀe c to ft h eS D F - 1 α, CXCR4 agonist, and CXCR4 antagonists on migration of
human CD34+ cells was assessed in transwell migration experiments. The fold increase in migration upon treatment with these compounds
was determined in relation to the corresponding control in four to eight independent experiments. SDF-1α induced chemoattraction in a
dose-dependent manner. The same concentration of the peptide agonist CTCE-0214 and the peptide antagonist CTCE-9908 did not have
any signiﬁcant eﬀect on migration of CD34+ cells although there was a signiﬁcant eﬀect using much higher concentrations of CTCE-0214.
(a) ∗P<. 05. SDF-1α has a dose-dependent eﬀect on the polarization and podia formation of CD34+ cells. The morphology was analyzed in
ﬁveindependentexperimentswithsimultaneouscomparisonofthecompounds.ThepeptideagonistCTCE-0214andthepeptideantagonist
CTCE-9908 also showed a signiﬁcant eﬀect on uropod formation. (b) ∗P<. 05.
control experiments [9]. The percentage of polarized cells
with a prominent uropod increased under treatment with
SDF-1α in a concentration-dependent manner (up to 40%±
10% in SDF-1α 500ng/mL). Surprisingly, a signiﬁcant in-
crease in podia-forming cells was also achieved by the ago-
nist CTCE-0214 or the antagonist CTCE-9908. Thus, these
compounds might induce podia formation, probably via cy-
toskeletal rearrangements, but did not induce directed mi-
gration in concentrations between 10ng/mL to 500ng/mL.
AMD3100 did not aﬀect uropod formation (Figure 2(b)).
3.3. Effectsonsurvivalandproliferation
CD34+ cells were cultured in a culture medium supple-
mented with a cytokine cocktail (Epo, IL-3, IL-6, GM-CSF,
SCF, bFGF, and IGF-1) as described before [28, 29]. A high
cell viability was observed and less than 1% of the cell popu-
lationwasPIpositiveupontreatmentwithanyoftheCXCR4
agonists or antagonists. Most of the cells divided up to six
times after ﬁve days and cell division kinetics were not af-
fected by the compounds (Figures 3(a) and 3(b)). Thus, we
reasoned that a cytokine deprived culture condition might
be more suitable for analysis of survival and proliferation.
Culturing of enriched CD34+ cells in RPMI-1640 medium
with 20% FCS for seven days without any supplements re-
sulted in a reduced cell viability. According to forward scat-
ter (FSC) and side scatter (SSC), the cell population could
be clearly distinguished and represented about 30% of the
counted events. About 3.1% ± 0.9% of these cells were pos-
itive for propidium iodide (Figure 3(a)). The addition of
SDF-1α, CTCE-0214, CTCE-9908, or AMD3100 (500ng/mL
each) did not have any signiﬁcant impact on the cell num-
ber according to counted events, nor on the percentage of
PI positive cells (3.9% ± 0.7%; 3.0% ± 0.4%; 2.0% ± 1.3%;
3.4%±1.2%; 3.3%±0.5%, resp.). Of the remaining cells ap-
proximately 50% have divided as determined by dilution of
CFSE dye. SDF-1α and its analogs did not have any signif-
icant eﬀect on proliferation of CD34+ cells although there
was a tendency towards more cell divisions with CTCE-0214
(Figure 3(c)).
3.4. Effectsonadhesion
The SDF-1α/CXCR4 pathway plays a signiﬁcant role in hom-
ing and mobilization of hematopoietic stem cells. Human
mesenchymal stromal cells from bone marrow (BM-MSC)
represent a surrogate model for studying molecular mecha-
nisms of adhesion of human HPC towards the cellular de-
terminants of the niche. This heterotypic cell-cell adhesion
was analyzed using a novel adhesion assay [33]. By means of
gravitational force, HPCs were separated into those adher-
ent to the feeder layer and those that dropped to the orig-
inal covering glass upon inversion of the culture prepara-
tions. Furthermore, we have analyzed adhesion of HPC to a
protein coated glass surface without feeder layer cells. About
20% ± 1% of the cells demonstrated unspeciﬁc binding to
BSA and 28% ±6% remained attached to ﬁbronectin coated
surfaces [33]. In contrast, 74% ±10% of the CD34+ adhered
to BM-MSC under control conditions without addition of
SDF-1α analogs. As demonstrated in Figure 4, there was aAnne Faber et al. 5
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Figure 3:EﬀectsonProliferation.CD34+ cellswerestainedwithCFSEandsubsequentlygrownfor5daysinculturemediumwithacytokine
cocktail (Epo, IL-3, IL-6, GM-CSF, SCF, bFGF, and IGF-1) or for 7 days in culture medium without cytokine supplements. Cultivation with
the cytokine cocktail resulted in a very high viability of > 95%, whereas without cytokines the cell population could be distinguished accord-
ing to forward scatter (FSC) and side scatter (SSC) from cell fragments (black spots: PI positive; grey spots: PI negative). (a) The number of
cell divisions was estimated within the PI negative cell population by the dilution of CFSE dye. Whereas the CD34+ cells demonstrated a high
proliferation with the cytokine cocktail, only about 50% of the cells proliferated without these cytokines. (b) SDF-1α, the peptide agonist
CTCE-0214, the peptide antagonist CTCE-9908, and the nonpeptide antagonist AMD3100 did not have a signiﬁcant eﬀect on the fraction
of proliferating cells (c) nor on the percentage of PI negative cells (three independent experiments).6 Journal of Biomedicine and Biotechnology
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Figure 4: Eﬀects on adhesion. Adhesion of CD34+ cells was either
analyzed on protein-coated surfaces (white bars) or on mesenchy-
mal stromal cells (MSCs) from human bone marrow (black bars)
in culture media supplemented with SDF-1α, CTCE-0214, CTCE-
9908, or AMD3100. Adhesion was signiﬁcantly reduced by SDF-1α,
peptide agonist CTCE-0214, as well as by the mobilization agent
AMD3100 (three independent experiments; ‡P = .014; #P = .007;
†P = .7 ×10−4; ¶P = .002).
signiﬁcant reduction in cell adhesion upon treatment with
SDF-1α (55% ± 13%; P = .014), CTCE-0214 (46% ± 16%;
P = .7) and AMD3100 (32% ± 11%; P = 7 × 10−5). The
peptide antagonist CTCE-9908 did not have an eﬀect on cell
adhesion (74% ±8%).
3.5. EffectsonsurfaceexpressionofCXCR4
Various reports demonstrated that SDF-1α induced internal-
izationoftheCXCR4receptor[38–40].Inthisstudy,wehave
analyzed surface expression of CXCR4 and CD34 either un-
der treatment with CXCR4 agonists and antagonist (n = 4)
or after two additional washing steps upon treatment with
CXCR4 agonists and antagonists (n = 4). In four individual
experiments withoutadditional washing steps, 41.6%±7.9%
of the cells within the CD34+ fraction expressed CXCR4 on
the cell surface and this proportion was even higher in the
residual CD34− cells (61.4% ± 14.9%, P = .07). Pretreat-
mentwithSDF-1αreducedtheCXCR4expressionwithinthe
CD34+ cells (30.0% ± 13.9%, P = .13). Detection of CXCR4
was signiﬁcantly reduced upon pretreatment with AMD3100
(6.5%±0.8%,P = .002).ThepeptideagonistCTCE-0214did
not show any eﬀect on CXCR4 expression (43.9% ± 12.9%),
whereas the peptide antagonist CTCE-9908 enhanced the
proportion of CXCR4+ cells (47.0% ± 6.1%, P = .02). A
representative experiment of four is shown in Figure 5.A d -
ditional washing steps with ice-cold PBS to remove SDF-1α
agonists and antagonists prior to antibody staining revealed
the same tendency, although CXCR4 detection was higher
upon removal of AMD3100 (control 32.8% ± 3.3%; SDF-1α
20.7% ± 5.2%, P = .06; CTCE-0214 31.2% ± 5.2%; CTCE-
9908 33.9% ± 4.7%; AMD3100 22.5% ± 6.1%, P = .02). In
addition, cells were permeabilized upon treatment with the
SDF-1α agonists and antagonists. In the control, nearly all
cells (98.45%) were positive for CXCR4 and no decrease in
CXCR4 detection was observed after cytokine stimulation.
4. DISCUSSION
To examine the potentials of agonists and antagonists of
CXCR4, we have monitored directed migration, podia for-
mation, adhesion behavior, and proliferation of human HPC
under the inﬂuence of SDF-1α, a peptide agonist of CXCR4
(CTCE-0214), a peptide antagonist (CTCE-9908), and a
nonpeptide antagonist (AMD3100). Despite the rationale
that all of the SDF-1α analogs act on the same CXCR4 recep-
tor, we have demonstrated that these compounds might have
diﬀerential eﬀects on diﬀerent functional properties of SDF-
1α. It might be speculated that the SDF-1α analogs induce
diﬀerent conformational changes of the CXCR4 receptor or
thatothercoreceptorsareinvolved.Theseresultssuggestthat
the signal cascade induced by SDF-1α is not a monocausal
succession (SDF-1α binding to CXCR4 activating G-proteins
further activating downstream mediators) but rather a com-
plex network [6, 20]. Analysis of the downstream targets in
signal cascades such as calcium ﬂux or MAPKp42/42 acti-
vation is concurrently under way and might help to clarify
some of the eﬀects of CXCR4 agonists and antagonists.
SDF-1α is a powerful chemoattactant for primitive hu-
man hematopoietic progenitor cells [20, 41, 42]. Chemo-
taxis of CD34+ cells can be enhanced by SDF-1α in a
dose-dependent manner in concentrations ranging from
0.01μg/mL to 0.5μg/mL [9, 41]. Zhong et al. have previously
reported that the peptide agonist CTCE-0214 can also en-
hance migration of CD34+ c e l l si nat r a n s w e l lm i g r a t i o na s -
say [24]. These authors used concentrations of CTCE-0214
up to 100μg/mL and they described a six-fold increase in
migration of CD34+ cells from mobilized peripheral blood
as compared to unstimulated cells. In analogy, we observed a
moderate increase in cell migration using 100 μg/mL CTCE-
0214. However, using the same concentration range as for
SDF-1α (0.01μg/mL–0.5μg/mL), we demonstrated that nei-
ther CTCE-0214 nor CTCE-9908 or AMD3100 exerted sig-
niﬁcant eﬀects on migration of CD34+ cells from umbilical
cord blood. Thus, in comparison to SDF-1α and on a μgt o
μg basis, none of the agonists and antagonists were a potent
chemoattractant.
Wehavepreviouslydemonstratedthattheprimitive frac-
tion of slow dividing cells has a higher proportion of elon-
gated cells with a prominent uropod [28]. Furthermore,
HPCs adhere to supportive feeder layer cells with their uro-
pod at the trailing edge [37]. We and others have previously
demonstrated that SDF-1α aﬀects podia formation in var-
ious AML cell lines [9, 10]. In this study, we have shown
thatpolarizationandformationofanprominenturopodcan
be increased in CD34+ cells in a dose-dependent manner
by SDF-1α.T h i se ﬀect can probably be attributed to cy-
toskeleton rearrangements of actin-containing protrusionsAnne Faber et al. 7
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Figure 5: Eﬀects on surface levels of CXCR4 detected by ﬂow cytometry. Surface expression of CXCR4 (phycoerythrin; PE) and CD34
(allophycocyanin, APC) was analyzed on the surface of CD34+ enriched cells upon treatment with CXCR4 agonist and antagonist without
additionalwashingsteps.Demarcationofautoﬂuorescenceisindicatedbyblacklines.TheproportionofCXCR4+ cellswashigherinresidual
CD34− cells compared to the CD34+ fraction. CXCR4 detection was reduced upon treatment with SDF-1α and AMD3100. The peptide
agonist CTCE-0214 did not aﬀect the proportion of CXCR4+ cells, whereas the peptide antagonist CTCE-9908 increased this proportion.
Concentration of cytokines was 500ng/mL. Representative plots of four independent experiments are shown.
[43]. Surprisingly the peptide agonist and the peptide an-
tagonist also had a signiﬁcant impact on podia formation
although they did not induce directed migration. Thus, di-
rected migration in chemotaxis does not directly correlate
with podia formation.
Survival of CD34+ cellsinculturecouldbemaintained to
a limited extent by cytokines such as thrombopoietin (TPO),
stem cell factor (SCF), or ﬂt-3 ligand alone or in combina-
tion. Some studies have indicated that SDF-1α also might
have a moderate eﬀect on survival of CD34+ cells and this
eﬀect was signiﬁcantly enhanced in combination with other
cytokines [11–13, 15]. In analogy, it has been shown that
CTCE-0214 alone did not increase the viability of CD34+
cells, whereas a synergistic activity of CTCE-0214 in con-
junction with other growth factors has been described [23].
In this study, we have demonstrated that neither the na-
tive molecule SDF-1α nor the agonist nor the antagonists
alone had a signiﬁcant impact on proliferation or survival of
CD34+ cells. We cannot exclude the possibility that SDF-1α
agonists or antagonists might induce proliferation when ap-
plied in conjunction with other chemokines as described be-
fore.IthasbeenreportedthatAMD3100wasabletomobilize
a CD34+ population with higher proliferative potential than
upon mobilization with G-CSF [44]. These observations are
most likely due to diﬀerent subfractions of CD34+ cells mo-
bilizedbyAMD3100aswedidnotobserveasigniﬁcanteﬀect
of this compound on proliferation.
Human BM-MSC represents a surrogate in vitro model
for studying the speciﬁc molecular mechanisms of adhesion
of HPC towards the cellular niche [33]. The adhesion as-
say described here was used to test diﬀerent compounds in
parallel and it might be suitable for testing new chemical
compounds that play a role on heterotypic cell-cell adhesion.
We have demonstrated in this study that adhesion of CD34+
cells to BM-MSC was signiﬁcantly reduced upon treatment
with SDF-1α, CTCE-0214, or AMD3100. In contrast, the an-
tagonist CTCE-9908 did not aﬀect cell adhesion. Other au-
thorsdemonstratedthatcelladhesionisincreasedbySDF-1α
[43, 45, 46]. However, in these studies adhesion was usually
analyzed upon interaction with extracellular matrix compo-
nents such as ﬁbronectin, and nonadherent cells were sepa-
rated by a washing step at one time point. In contrast, in our
standardized adhesion assay without shear stress, gravita-
tionalforceisaﬀectingcell-cellinteractionoveratimecourse8 Journal of Biomedicine and Biotechnology
of one hour. An explanation for the increased migratory ac-
tivity upon treatment with SDF-1α is that cell adhesion is
temporarily loosened and these cells would then detach and
add to the no-adherent fraction. Furthermore, it has been re-
ported that CXCR4 activation is also important for mediat-
ingspeciﬁcmigrationofbonemarrowstromalcellsalthough
this receptor seems to be only present at very low levels at the
surface of MSC [47–49]. Thus, in contrast to previous stud-
ies that analyzed adhesion of HSC to ﬁbronectin, we have
analyzed adhesion to MSC with and without the addition of
SDF-1α, its agonists, and antagonists. Our results are com-
patible with the observation that both agonist and antago-
nists of the SDF-1α/CXCR4 axis have been shown to eﬀec-
tively mobilize primitive HPC to the peripheral blood. Ele-
vated plasma levels of SDF-1α induce mobilization of HPC
to the peripheral blood [16]. In the murine system, injec-
tion of CTCE-0214 led to an increase of primitive HPC in
the peripheral blood [24]. AMD3100 has been reported to
mobilize HSC from the bone marrow to peripheral blood ef-
ﬁciently [26]. The increase of HPC is rapid after a single in-
jection and the corresponding clinical trials have been con-
ducted successfully in patients who have failed to respond to
granulocyte colony stimulating factors alone.
In our previous work, we provided evidence that
more primitive fractions of HPC adhere signiﬁcantly more
than their more diﬀerentiated counterparts (CD34+ versus
CD34−, CD34+CD38− versus CD34+CD38+, slow dividing
fraction versus fast dividing fraction of CD34+CD38− cells)
[33]. Furthermore, there is evidence that AMD3100 and G-
CSF might mobilize a more primitive and hence multipotent
HPC population than G-CSF alone [26, 27]. Thus, it could
be speculated that CXCR4 agonists and antagonists aﬀect the
speciﬁc interaction of primitive HPCs and their cellular mi-
croenvironment.
The proportion of CXCR4+/CD34+ cells was reduced
upon stimulation with SDF-1α and AMD3100. Buul et
al. have previously demonstrated that SDF-1α induced re-
distribution and internalization of a CXCR4-fusion pro-
tein in KG1a cells [38]. This phenomenon has also been
shown for other leukemic cell lines [40]. Dar et al. reported
that CXCR4-dependent internalization of and resecretion of
SDF-1α by endothelial and stromal cells played an essential
role to establish an SDF-1α gradient that assisted directed
migration of CD34+ cells [2]. Multiple residues within the
CXCR4 C-terminal tail appeared to mediate this receptor in-
ternalization[39].Inthiscontext,ourdatahaveprovidedev-
idence that CXCR4 is also internalized in CD34+ cells upon
stimulation with SDF-1α. Hatse et al. reported long-term in-
teraction of AMD3100 with CXCR4 that blocked binding of
the same antibody (clone 12G5) at the cell membrane [50].
Furthermore, they described that AMD3100 inhibits SDF-
1α-inducedinternalizationofCXCR4inU87-CD4cells.This
is in line with our observation that CXCR4 surface detection
by the 12G5 antibody is abolished by AMD3100, whereas
additional washing steps increased the detection of CXCR4.
Thus, furtheranalysisofinternalized receptor revealedno ef-
fect of AMD3100 treatment on intracellular CXCR4 detec-
tion. On the other hand, our results provide evidence that
CTCE-0214 does not aﬀect receptor internalization, whereas
the peptide antagonist CTCE-9908 enhanced the proportion
of CXCR4+ cells, and this observation is compatible with re-
duced receptor internalization. The G-protein coupled re-
ceptor CXCR4 is not an adhesion protein itself. However, re-
cently crosstalk between the CXCR4/SDF-1α axis and other
adhesion proteins such as VLA-4, VLA-5, and CD164 has
been shown [51], and hence internalization of CXCR4 upon
stimulation with agonists and antagonists might be asso-
ciated with redistribution of these adhesion proteins, and
thereby reducing intercellular adhesion.
Peptide and nonpeptide analogs have several advantages
compared to the native molecules. The ease of synthesis,
lower manufacturing costs, improved bioavailability, and
lower immunogenicity of peptides or analogs may make
them more accessible for clinical applications. Recent results
have also suggested that the SDF-1α/CXCR4 axis is also used
by cancer cells for metastatic dissemination in many types of
solid tumours [52, 53]. In addition to mobilization of HPC,
CXCR4agonistsandantagonistsmight havethepotential for
treatmentofmetastaticdiseases.Ifconﬁrmed,preciseknowl-
edge of homing and adhesion and their speciﬁc manipula-
tion might have signiﬁcant therapeutic potentials and impli-
cations.
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